Decibel Therapeutics Announces Foundational Publication. known


BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) – Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company committed to the discovery and development of transformative treatments to restore and improve hearing and balance, today announced that it that the results of a study of noise-induced inner ear damage conducted in collaboration with the University of Maryland School of Medicine (UMSOM) and the Karolinska Institute (KI) were in. released Cell reports.

The aim of the study was to create an atlas of the gene expression changes across the cell types of the inner ear after noise damage. Decibel contributed gene expression data from inner ear neurons and stria vascularis cells before and after noise damage, which was then combined with similar data from hair cells, non-sensory support cells, and immune cells generated by UMSOM and AI. The study represents the first comprehensive such analysis and provides a fundamental data set that can be obtained for future studies of the inner ear.

“We believe that the lack of approved therapies for hearing and balance disorders is in part due to the lack of molecular characterization of the complex cell biology of the inner ear. That is why we built our platform to meet this challenge. We were excited to use our data and expertise in inner ear biology to advance this analysis, which can help identify therapeutics that counter the observed trends in gene expression that occur after exposure to noise, ”said Joe Burns, Ph .D., Vice President Discovery at Decibel Therapeutics. “This work is evidence of how data sharing and analysis can help researchers across the field connect the dots to understand the mechanisms behind inner ear damage and explore new treatment approaches. We look forward to continuing to work with our colleagues at the University of Maryland and other leaders in the field. “

Decibel’s platform is based on the application of proprietary analyzes of gene expression in the cochlea and vestibule and a comprehensive single cell database with gene expression profiles of all known cell types in the inner ear. This comprehensive data set comprises over three million cellular transcriptional expression profiles from the cochlea and vestibule of several mammalian species. The dataset covers key stages of development from embryo to adulthood and includes data generated after various disturbances including noise, aging and chemical exposure.

About decibel therapeutics
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to the discovery and development of transformative treatments to restore and improve hearing and balance, one of the largest unmet need in medicine. Decibel has built a proprietary platform that integrates single cell genomics and bioinformatic analysis, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies that aim to selectively replace genes used to treat congenital, monogenic hearing loss and to regenerate inner ear hair cells to treat acquired hearing and balance disorders. Decibel’s pipeline, including its leading gene therapy program, DB-OTO for the treatment of congenital monogenic hearing loss, is intended to realize our vision of creating a world of connection for people with hearing and balance disorders. For more information about Decibel Therapeutics, please visit or follow us on Twitter.

Investor contact:
Julie Seidel
Stern Investor Relations, Inc.
[email protected]

Media contact:
Chris Railey
Ten-bridge communication
[email protected]


Comments are closed.